内容来源：https://www.geekwire.com/2026/selling-sunshine-from-seattle-solius-raises-23m-to-launch-new-at-home-light-therapy-device/

内容总结：

西雅图初创公司推出家用紫外线光疗设备，解决全球10亿人维生素D缺乏问题

总部位于华盛顿州班布里奇岛的Solius Labs近日宣布获得2300万美元A轮融资，并同步推出售价2995美元的Solius Pro家用紫外线B（UVB）光疗设备。这款壁挂式设备约为一台大号笔记本电脑大小，通过扫描用户皮肤自动计算个性化UVB剂量，以293纳米波长精准照射背部，每周一次、每次不到5分钟，全程可通过手机应用控制。

Solius首席执行官Chris Kiple表示，UVB光疗并非新技术，但该公司首次将其变得安全、易用且随时随地可高效使用。该设备已获美国食品药品监督管理局（FDA）作为II类医疗器械批准，专门用于刺激22岁及以上人群的维生素D生成。

传统UVB光疗通常只在皮肤科诊所进行，用于治疗湿疹、银屑病和白斑病等皮肤问题。Solius独有的皮肤扫描系统（正在申请专利）可自动计算剂量，避免因剂量不足无效或过量损伤皮肤的风险。Kiple强调，这是首家开发出无需临床医生在场即可自动计算剂量的传感器的公司。

Solius成立于2013年，最初开发大型光疗亭，部署在临床机构和药房。2023年Kiple出任CEO后，带领团队对公司进行资本重组，将技术小型化、价格更亲民地推向家庭市场。本轮融资由Lauder Partners领投，该公司现有员工20余人，正在积极招聘工程、质量、销售和市场岗位。

Solius Pro目前已收获超1000份预订单，预计7月开始发货。Kiple看好其从家用直供消费者到医生诊所、皮肤科、健康会所等多渠道市场前景。

全球约有10亿人受维生素D缺乏困扰，研究显示缺乏日照与季节性情感障碍、骨密度下降和心血管疾病等密切相关。身处以阴雨闻名、每年九个月不见阳光的太平洋西北地区，Kiple坦言这正体现了Solius Pro的价值：“我们学会了躲避阳光，生活方式也让人们整天待在室内。如何让人随时随地获得阳光的益处？这就是我们的答案。”

中文翻译：

西雅图地区一家曾邀请人们走进发光亭接受光疗的初创公司，如今正将同样的技术带入家庭。
总部位于华盛顿州班布里奇岛的Solius Labs周三宣布获得2300万美元A轮融资，并同时推出Solius Pro：一款售价2995美元的UVB（中波紫外线）光疗设备，可供家庭和专业场所使用。
这款壁挂式设备大小与一台大型笔记本电脑相当，可扫描用户皮肤，计算出针对293纳米波长的个性化UVB光剂量。Solius Pro每周仅需一次不到五分钟的治疗，将光疗作用于用户背部，并通过智能手机应用程序控制。
“UVB并不新鲜，”Solius首席执行官克里斯·基普尔告诉GeekWire，“我们只是首家以高效方式让UVB变得安全、易用且随时可得的企业。”
据该公司称，美国食品药品监督管理局已根据为该技术创建的专属产品代码SGZ，将Solius Pro批准为II类医疗器械。根据FDA文件，该批准专门针对22岁及以上人群的体内维生素D生成刺激。
UVB光疗传统上仅在皮肤科诊所提供，通常用于治疗湿疹、银屑病和白癜风等皮肤疾病。
皮肤扫描系统已申请专利，是Solius安全性声明的核心。由于UVB反应因皮肤类型差异显著，个性化剂量至关重要——剂量过小无效，过大则有皮肤损伤风险。基普尔表示，Solius是首家开发出无需临床医生在场即可自动计算剂量的传感器的公司。
成立于2013年的Solius最初开发了大型步入式光疗亭，部署于临床机构和药房——包括2018年在加拿大温哥华的首个公共安装点——同时在西雅图地区进行临床试验。
基普尔于2023年加入并担任CEO，他带来了来自博塞尔市Ventec Life Systems的团队——该公司曾在新冠疫情期间与通用汽车合作扩大重症护理呼吸机生产。他着手对Solius进行资本重组，并将其技术重塑为更小巧、更实惠的家用设备。
本轮A轮融资由Lauder Partners领投，参与方包括风险投资基金、家族办公室及个人投资者。Solius现有员工略超20人，目前正在工程、质量、销售与市场等岗位积极招聘。
该公司表示，在Solius Pro发布前已收到超过1000份预订单，该设备现已在其网站上架，预计将于7月开始发货。基普尔认为该设备在多个市场均有发展机遇，从直接面向消费者的家庭使用，到医生办公室、皮肤科诊所及健康养生机构。
Solius瞄准的是一个日益严重的健康问题——全球约10亿人受维生素D缺乏影响，而研究越来越将阳光照射不足与季节性情感障碍、骨密度下降及心血管疾病等一系列状况联系起来。
对于一家销售阳光的公司而言，太平洋西北地区恰如其分地成为其大本营，而基普尔（在班布里奇岛办公）并不回避这种讽刺意味。
“我们学会了躲避阳光，我们的生活方式也已演变为回避阳光，”他说，“西雅图的科技从业者——微软、亚马逊——我们整天待在室内。尤其是在西雅图，一年中有九个月都见不到太阳。”
基普尔表示，这正是Solius Pro的意义所在。
“我们如何让你无论何时何地都能获得阳光的益处？”

英文来源：

A Seattle-area startup that once asked people to step inside a glowing kiosk for light therapy is now bringing that same technology into the home.
Bainbridge Island, Wash.-based Solius Labs announced $23 million in Series A funding on Wednesday along with the launch of the Solius Pro: a $2,995 UVB (Ultraviolet B) light therapy device for home and professional use.
The device, which hangs on a wall and is about the size of a large laptop computer, scans a user’s skin to calculate a personalized dose of UVB light at a targeted 293-nanometer wavelength. Solius Pro delivers light therapy to the user’s back in a single weekly session of less than five minutes, and is controlled via a smartphone app.
“UVB is not new,” Solius CEO Chris Kiple told GeekWire. “We’re just the first that has made UVB safe and usable and accessible anytime in an efficient way.”
The Food and Drug Administration cleared the Solius Pro as a Class II medical device under a product code — SGZ — created for the technology, according to the company. That clearance specifically covers stimulating the body’s vitamin D production in people 22 and older, according to FDA filings.
UVB light therapy has traditionally been available in dermatology clinics, where it’s typically used to treat skin conditions including eczema, psoriasis and vitiligo.
The skin-scanning system is patent-pending and central to Solius’s safety claim. Because UVB response varies significantly by skin type, a personalized dose is essential — too little delivers no benefit, too much risks skin damage. Kiple said Solius is the first company to develop a sensor that can calculate that dose automatically, without a clinician present.
Founded in 2013, Solius originally developed large walk-in light therapy kiosks, deploying them in clinical settings and pharmacies — including its first public installation in Vancouver, B.C., in 2018 — while running clinical trials in the Seattle area.
Kiple joined as CEO in 2023, bringing a team from Bothell-based Ventec Life Systems — which had partnered with General Motors to scale critical care ventilator production during COVID. He set about recapitalizing Solius and reinventing its technology as a smaller, more affordable home device.
The Series A round was led by Lauder Partners and included venture capital funds, family offices and individual investors. Solius has just over 20 employees and is actively hiring across engineering, quality, sales and marketing roles.
The company says it has recorded more than 1,000 pre-orders ahead of the Solius Pro launch, with the device now available on its website and shipping expected to begin in July. Kiple sees opportunity across multiple markets, from direct-to-consumer home use to doctors’ offices, dermatology clinics and wellness facilities.
Solius is targeting a significant and growing health problem — vitamin D deficiency affects an estimated 1 billion people worldwide, and research increasingly links lack of sun exposure to a range of conditions including seasonal affective disorder, bone density loss and cardiovascular disease.
For a company selling sunshine, the Pacific Northwest turns out to be a fitting home base, and Kiple, who works out of Bainbridge Island, doesn’t shy away from the irony.
“We have learned to avoid the sun, and our lifestyles have evolved to avoid the sun,” he said. “Tech workers in Seattle — Microsoft, Amazon — we’re all inside all the time. In Seattle, in particular, we don’t see the sun for nine months out of the year.”
That, Kiple said, is precisely the point of Solius Pro.
“How do we give you that benefit of the sun anytime, anywhere?”